UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from__________ to __________ Commission File No.: 000-09881 SHENANDOAH TELECOMMUNICATIONS COMPANY (Exact name of registrant as specified in its charter) Virginia ...

STAG INDUSTRIAL ANNOUNCES THIRD QUARTER 2025 RESULTS Boston, MA — October 29, 2025 - STAG Industrial, Inc. (the "Company") (NYSE:STAG), today announced its financial and operating results for the quarter ended September 30, 2025. The Company will host a conference call tomorrow, Thursday, October 30, 2025 at 10:00 a.m. (Eastern Time), to discuss the quarter's results and provide information about acquisitions, operations, capital markets and corporate activities. Details of the call can be found at the end ...

Exhibit 99.1 Sun Country Airlines Reports Third Quarter 2025 Results Revenue of $256 million, highest third quarter on record GAAP diluted EPS of $0.03, operating income of $10 million and margin of 3.9% Adj. diluted EPS of $0.07, adj. operating income of $12 million and adj. margin of 4.8% Thirteenth consecutive profitable quarter (1) (2) (2) (2) MINNEAPOLIS. October 29, 2025. Sun Country Airlines Holdings, Inc. ("Sun Country Airlines," "Sun Country," the "Company") (NASDAQ: SNCY) today reported financial ...

Exhibit 99.1 Microsoft Cloud and AI Strength Drives First Quarter Results REDMOND, Wash. — October 29, 2025 — Microsoft Corp. today announced the following results for the quarter ended September 30, 2025, as compared to the corresponding period of last fiscal year: "Our planet-scale cloud and AI factory, together with Copilots across high value domains, is driving broad diffusion and real-world impact," said Satya Nadella, chairman and chief executive officer of Microsoft. "It's why we continue to increase ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-08325 _____________________________________________________________ MYR GROUP INC. (Exact name of registrant as specif ...

Exhibit 99.1 eBay Inc. Reports Third Quarter 2025 Results San Jose, California, October 29, 2025 – eBay Inc. (Nasdaq: EBAY), a global commerce leader that connects millions of buyers and sellers around the world, today reported financial results for its third quarter ended September 30, 2025. "Q3 was another strong quarter for eBay, reflecting continued momentum across our marketplace and disciplined execution of our strategy," said Jamie Iannone, Chief Executive Officer of eBay. "We're transforming the eBa ...

Revenue Performance - Revenue for Q3 2025 was $265.2 million, a 39% increase from $191.5 million in Q3 2024[4] - Total revenue for Q3 2025 reached $265.196 million, a 38.6% increase from $191.476 million in Q3 2024[28] - Oncology revenue grew 31% to $184.4 million, driven by a 40% increase in test volume[4][6] - Oncology revenue for Q3 2025 was $184.402 million, up 30.6% from $141.197 million in Q3 2024[28] - Screening revenue reached $24.1 million, primarily from approximately 24,000 Shield tests[4][6] - Biopharma and Data revenue increased by 18% to $54.7 million, attributed to milestone achievements[4][6] - Biopharma and data revenue increased to $54.731 million in Q3 2025, compared to $46.547 million in Q3 2024, reflecting a growth of 17.5%[28] Profitability and Margins - Gross profit was $171.6 million, with a gross margin of 65%, up from 61% in the prior year[5][6] - Non-GAAP gross margin for Q3 2025 was 66%, compared to 63% in Q3 2024[7][6] - Net loss for Q3 2025 was $92.7 million, an improvement from a net loss of $107.8 million in Q3 2024[9] - GAAP net loss for Q3 2025 was $92.725 million, an improvement from a net loss of $107.754 million in Q3 2024[31] - Non-GAAP net loss per share for Q3 2025 was $0.39, compared to $0.45 in Q3 2024[31] Cash Flow and Financial Position - Free cash flow for Q3 2025 was $(45.8) million, compared to $(55.3) million in the same period last year[11] - Free cash flow for Q3 2025 was $(45.763) million, a decrease from $(55.258) million in Q3 2024[35] - Cash and cash equivalents increased to $580.013 million as of September 30, 2025, up from $525.540 million at the end of 2024[26] - Total assets decreased to $1,276.786 million as of September 30, 2025, down from $1,485.609 million at the end of 2024[26] - Total liabilities slightly increased to $1,631.259 million as of September 30, 2025, compared to $1,625.256 million at the end of 2024[26] - Total stockholders' deficit widened to $(354.473) million as of September 30, 2025, compared to $(139.647) million at the end of 2024[26] Guidance and Future Outlook - The company raised its 2025 revenue guidance to $965 to $970 million, reflecting a year-over-year growth of approximately 31%[1][12] - Operating expenses for Q3 2025 were $270.6 million, up from $234.3 million in the prior year, mainly due to commercial team expansion[8]

MIMEDX Announces Record Revenue for Third Quarter 2025 Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Conference Call Today, October 29, 2025, at 4:30 PM ET MARIETTA, Ga ...

Financial Performance - Revenues for the quarter ended September 30, 2025, were $60,082, an increase of $11,438 or 23.5% compared to $48,644 for the same quarter in 2024[106] - Gross profit for the quarter ended September 30, 2025, was $45,993, reflecting an increase of $9,555 or 26.2% from $36,438 in the prior year, with a gross margin of 76.6%[110] - Net income for the quarter ended September 30, 2025, was $708, compared to a net loss of $1,858 in the same quarter of 2024[107] - Revenues for the nine months ended September 30, 2025 increased by $27,371, or 19.8%, to $165,304 compared to $137,933 for the same period in 2024[115] - Gross profit for the nine months ended September 30, 2025 increased by $18,542, or 17.8%, to $122,944, with a gross margin of 74.4% compared to 75.7% in 2024[117] - Net loss for the nine months ended September 30, 2025 was $2,547, a significant improvement from a net loss of $10,414 in 2024[120] Costs and Expenses - Total costs and expenses for the quarter ended September 30, 2025, were $44,081, a 19.9% increase from $36,754 in the same quarter of 2024[111] - Sales and marketing expenses increased by 35.7% to $25,680 for the quarter ended September 30, 2025, compared to $18,924 in 2024[111] - Total costs and expenses for the nine months ended September 30, 2025 were $121,021, an increase of 10.3% from $109,706 in 2024, driven primarily by higher sales and marketing costs[118] - Research and development costs for the quarter ended September 30, 2025, were $7,565, representing an 8.1% increase from $6,996 in the same quarter of 2024[111] - Research and development costs decreased by 2.6% to $20,509 for the nine months ended September 30, 2025, primarily due to lower product development expenses[119] Cash Flow and Liquidity - Cash and cash equivalents and investments increased by $2,309 to $35,791 as of September 30, 2025, primarily due to proceeds from stock options and the release of restricted cash[123] - Net cash used in operating activities decreased by $1,974, or 47.0%, to $2,226 for the nine months ended September 30, 2025, reflecting a decrease in net loss[126] - Net cash provided by financing activities increased by $4,613 to $5,933 for the nine months ended September 30, 2025, primarily due to increased proceeds from the exercise of stock options[128] - The current ratio improved to 4.1x as of September 30, 2025, compared to 3.2x at December 31, 2024, indicating stronger liquidity[124] Business Developments - The company expanded coverage for nerve repair, increasing the total number of new lives covered in 2025 to approximately 18.1 million, with coverage among commercial payers exceeding 64%[106] - The FDA accepted the filing of the Biologics License Application for Avance Nerve Graft, with a new PDUFA goal date of December 5, 2025, following a major amendment submission[106] - The company discontinued its case stock sales program for Avance Nerve Graft, positively impacting revenue by approximately $1.6 million, or about 3%[109] - The company discontinued its case stock sales program for Avance Nerve Graft, positively impacting revenue by approximately $1.6 million, or about 1%[116] Debt and Interest - As of September 30, 2025, the outstanding principal amount of loans under the Credit Facility was $50,000[137] - Interest on loans under the Credit Facility is calculated at 7.5% plus the greater of Adjusted SOFR or 2.0%, with a minimum interest rate of 9.5%[137] - At September 30, 2025, the Adjusted SOFR was 11.89%[137] - A 100 basis points increase in interest rates would increase annual interest expense by approximately $500[137] - Changes in the Adjusted SOFR rate may affect interest expense associated with the Credit Facility[137]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38377 BRIGHTSPIRE CAPITAL, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) ...